Gleevec

Phase 3Gene therapy

Novartis

Gleevec is one of 312 small molecule programs targeting Polycythemia Vera. It is currently in Phase 3.

Indications

Total Trials

Active Trials

311

Competitors

Pipeline

Status by Indication[3][1]

Indication

Polycythemia VeraActive, not recruiting

Thymic CarcinomaActive, not recruiting

Thyroid CarcinomaActive, not recruiting

Pulmonary HypertensionActive, not recruiting

Chronic Myelogenous LeukemiaActive, not recruiting

Plexiform NeurofibromaActive, not recruiting

MelanomaActive, not recruiting

Prostate CancerActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Myelodysplastic SyndromesActive, not recruiting

Polycythemia VeraPhase 2

Active, not recruiting

Thymic CarcinomaPhase 1

Active, not recruiting

Thyroid CarcinomaPhase 1/Phase 2

Active, not recruiting

Pulmonary HypertensionPhase 2

Active, not recruiting

Chronic Myelogenous LeukemiaPhase 3

Active, not recruiting

Plexiform NeurofibromaPhase 2

Active, not recruiting

MelanomaPhase 1/Phase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 2

Active, not recruiting

Myelodysplastic SyndromesPhase 2

Active, not recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Gleevec

Novartis

Phase 3

1 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Viagra

VViatris Specialty LLC

Preclinical

1 6

Triptorelin Pamoate

Ipsen

Preclinical

2 7

Ifex

BBaxter Healthcare Corporation

Preclinical

—8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Xylocaine

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Myelogenous Leukemia4 trials

Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Completed· Novartis logo

Novartis·Phase 4·NCT00081926·112 enrolled

Late Chronic Phase Chronic Myelogenous Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01092741·47 enrolled

High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00050531·94 enrolled

Show 1 more trial

Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00040105·26 enrolled

Chronic2 trials

Therapy of Early Chronic Phase CML With Gleevec

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00048672·50 enrolled

Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00038649·117 enrolled

Plexiform Neurofibroma2 trials

Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas

Completed·KKent Robertson·Phase 1/2·NCT01140360·21 enrolled

Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas

Completed·IIndiana University·Phase 2·NCT01673009·36 enrolled

Melanoma1 trial

Study of Temzolomide and Gleevec in Advanced Melanoma

Terminated·—·Phase 1/2·NCT00667953·32 enrolled

Myelodysplastic Syndromes1 trial

Gleevec/Low-Dose Ara-C Study for Elderly Patients With AML and Myelodysplastic Syndromes

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00451997·10 enrolled

11 more indications

Pulmonary Hypertension1 trial

Safety Study of Gleevec® in Children With Pulmonary Hypertension

Terminated·IIndiana University·Phase 2·NCT00583115·1 enrolled

Pediatric1 trial

Glivec Phase II Pediatric Study

Terminated·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT00180830·36 enrolled

Hypereosinophilic syndrome1 trial

Phase II Gleevec Idiopathic Hypereosinophilic Syndrome

Terminated·SSteven E. Coutre·Phase 2·NCT00230334·5 enrolled

Polycythemia Vera1 trial

Treatment of Polycythemia Vera With Gleevec

Completed·WWeill Medical College of Cornell University·Phase 2·NCT01120821·36 enrolled

Small Cell Lung Cancer1 trial

Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00248482·6 enrolled

Maintenance Therapy1 trial

Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00156286·20 enrolled

Acute Myeloid Leukemia1 trial

CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00955916·38 enrolled

Prostate Cancer1 trial

A Study of Imatinib and Docetaxel in Prostate Cancer

Completed·LLeonard Appleman·Phase 2·NCT00251225·49 enrolled

Pregnancy1 trial

A Global Imatinib and Nilotinib Pregnancy Exposure Registry

Completed· Novartis logo

Novartis··NCT01289054·4 enrolled

Thymic Carcinoma1 trial

Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma

Completed·IIndiana University School of Medicine·Phase 1·NCT00314873·11 enrolled

Thyroid Carcinoma1 trial

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT00354523·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for Gleevec. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gleevec compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gleevec. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Highest Phase: Phase 3[1]
Company: Novartis

Gleevec

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Myelogenous Leukemia4 trials

Chronic2 trials

Plexiform Neurofibroma2 trials

Melanoma1 trial

Myelodysplastic Syndromes1 trial

Pulmonary Hypertension1 trial

Pediatric1 trial

Hypereosinophilic syndrome1 trial

Polycythemia Vera1 trial

Small Cell Lung Cancer1 trial

Maintenance Therapy1 trial

Acute Myeloid Leukemia1 trial

Prostate Cancer1 trial

Pregnancy1 trial

Thymic Carcinoma1 trial

Thyroid Carcinoma1 trial

References

Drug Info

Quick Facts

Related News